Depression Screening and Management Approach

Screening Process and Interpretation

The American College of Physicians recommends administering the full PHQ-9 to assess the severity of depression and determine appropriate management based on the score, with immediate referral to mental health specialists for severe cases or suicidal ideation 1, 2
The PHQ-9 includes all nine DSM criteria for depression, with each item scored from 0-3 based on symptom frequency over the past two weeks 1
A traditional cutoff for the PHQ-9 is ≥10, though some guidelines recommend a cutoff score of ≥8 based on studies of diagnostic accuracy in specific populations 1, 3

Management Algorithm Based on PHQ-9 Score

For patients with none/mild symptomatology (PHQ-9 score 1-7), provide education about depression and normal stress responses, ensure patient has adequate coping skills and access to resources, and consider reassessment at future visits 4, 1
For patients with moderate symptomatology (PHQ-9 score 8-14), evaluate for pertinent history and specific risk factors for depression, consider referral to psychology or psychiatry for diagnostic evaluation, and offer low-intensity intervention options 4
For patients with moderate to severe/severe symptomatology (PHQ-9 score 15-27), make immediate referral to psychology and/or psychiatry for diagnosis and treatment, assess for risk of harm to self or others, and evaluate for medical or substance-induced causes of depressive symptoms 4, 1, 3

Special Considerations

Pay particular attention to item 9 of the PHQ-9, which assesses thoughts of self-harm, and immediate referral is required for patients with specific plans or intent for self-harm 1, 2, 3
Systematic implementation of depression screening and management requires clear protocols and designated responsibilities among the clinical team 1
Consider cultural sensitivity in assessment and treatment planning, tailor assessment for patients with learning disabilities or cognitive impairments, and be aware of the difficulty of detecting depression in older adults 1

Sensitivity and Specificity of the PHQ-9

Diagnostic Accuracy of the PHQ-9

The PHQ-9 has a sensitivity of 89.5% and specificity of 77.5% at a cut-off score of 11 for detecting major depressive disorder, making it an effective screening tool for depression in clinical settings 5
The positive predictive value (PPV) is 15.2% and negative predictive value (NPV) is 99.4%, indicating the tool is particularly strong at ruling out depression when scores are below the threshold 5
The American Academy of Pediatrics recommends the PHQ-9 as a validated depression screening tool that includes all nine DSM criteria for depression, with each item scored from 0-3 based on symptom frequency over the past two weeks, and has a sensitivity of 89.5% and specificity of 77.5% at a cut-off score of 11 5

Clinical Implications and Implementation

The American Society of Clinical Oncology recommends the PHQ-9 for depression screening at initial diagnosis, at appropriate intervals, and with changes in disease or treatment status 6
The PHQ-2, which consists of the first two items of the PHQ-9 assessing depressed mood and anhedonia, can be used as an initial screening step with a cut-off score of 3, and has a sensitivity of 73.7% and specificity of 75.2% for detecting major depressive disorder 5

Special Populations

The PHQ-9 Modified for Teens may be more appropriate when screening for depression in adolescents 5

Depression Screening with PHQ-9: Starting Age

Recommended Screening Age

The USPSTF clearly recommends universal adolescent depression screening starting at age 12 years and continuing through age 18 years, as this age group has validated depression screening tools and effective treatments available for identified patients 7, 8, 9
The U.S. Preventive Services Task Force (USPSTF) and the American Academy of Pediatrics GLAD-PC guidelines endorse beginning universal depression screening with the PHQ-9 at age 12 years 7, 10

Evidence Supporting Age 12 as the Starting Point

The PHQ-9 has been validated in adolescent primary care populations with a sensitivity of 89.5% and specificity of 77.5% at a cutoff score of 11 for detecting major depressive disorder 7
Most treatment trials demonstrating efficacy of SSRIs and psychotherapy were restricted to adolescents aged 12-14 years or older, providing the evidence base for intervention effectiveness in this age group 10, 11, 12
The mean age of onset for major depressive disorder in childhood and adolescence is approximately 14-15 years, with onset earlier in girls than boys 10, 13

Considerations for Younger Children

Studies examining depression screening in younger populations (ages 8-14 years) typically include depression as part of broader psychosocial screening rather than focused depression screening 14, 8
No screening studies included children younger than age 11 years when the USPSTF evaluated the evidence 11, 12, 15
The literature shows starting ages ranging from 8 to 14 years across various studies, but most depression-specific screening focuses on older age ranges 8, 9

Clinical Pitfalls to Avoid

Do not screen without having a clear protocol for managing positive screens, as screening alone without intervention does not improve outcomes 9
Consider using the PHQ-2 as an initial brief screen (cutoff ≥3), followed by the full PHQ-9 if positive, though this two-stage approach may miss some cases of suicidality that would be detected by the PHQ-9 7

Pediatric Self-Harm Screening Guidelines

Depression Screening Tools

The American Academy of Pediatrics recommends using the PHQ-9 for broader mental health screening, including self-harm risk, starting at age 12 years, with a sensitivity of 89.5% and specificity of 77.5% at a cutoff score of 11 for detecting major depressive disorder 16, 17
The PHQ-9 has been validated in adolescent primary care populations aged 12-18 years, with item 9 specifically assessing thoughts of self-harm, requiring immediate referral if positive 16, 17

Screening Implementation

The American Academy of Pediatrics suggests direct questioning about suicidal ideation should be embedded within depression symptom assessment, using questions such as "Have you ever thought about killing yourself or wished you were dead?" and "Have you ever done anything on purpose to hurt or kill yourself?" 18
Self-administered scales can be useful because adolescents may disclose suicidality on self-report that they deny in person 18

Critical Considerations

The American Academy of Pediatrics advises against assuming absence of current suicidal ideation means low risk, as patients who have previously attempted suicide remain at elevated risk if none of the factors that led to the attempt have changed 19
The American Academy of Pediatrics recommends recognizing that irritability, not sadness, may be the primary manifestation of depression in adolescents, and to look for cranky mood, oppositional behavior, and loss of interest in previously enjoyed activities 19

Age-Specific Screening

The US Preventive Services Task Force (USPSTF) evidence reviews for depression screening did not include children younger than age 11 years 17, 20

PHQ-9 Administration Guidelines

Appropriate Timing for PHQ-9 Administration

The PHQ-9 assesses symptoms over the past two weeks, making it suitable for administration at strategic intervals, such as initial screening and diagnosis, with the American Academy of Family Physicians recommending its use at annual visits, new patient evaluations, or when clinical concern arises 21, 22

Psychometric Design and Clinical Utility

The PHQ-9 was validated as a severity measure and screening tool, not a daily symptom tracker, with the National Institute of Mental Health suggesting its use as a periodic assessment tool to monitor treatment response 21

PHQ-9 Validation and Recommendations

Adult Population

The PHQ-9 is widely validated and recommended for adults across all age ranges in primary care and specialty settings, as supported by the Journal of Clinical Oncology 23
The tool has been validated in cancer outpatients, where a cutoff of ≥8 may show better diagnostic accuracy than the traditional cutoff of ≥10, according to the Journal of Clinical Oncology 24

Older Adults (Ages 65+)

The PHQ-9 is suitable for detection and monitoring in older adults with mild cognitive impairment (MCI) and mild dementia, as reported in Alzheimer's and Dementia 25
The tool is quick (3-5 minutes) and has been validated in individuals with MCI/dementia, with scores of 5-9 suggesting mild depression, 10-14 moderate depression, and >14 moderately severe/severe depression, as found in Alzheimer's and Dementia 25
The PHQ-9 becomes less suitable for more advanced and severe dementia and individuals with poor comprehension, as cognitive impairment can interfere with accurate self-reporting, according to Alzheimer's and Dementia 25
For older adults with more severe cognitive impairment, the Geriatric Depression Scale (GDS) may be preferable, as it is well-suited for detecting depression across the severity spectrum of MCI-dementia, as reported in Alzheimer's and Dementia 25

Screening and History‑Taking for Depression in Primary Care

Initial Screening Questions

In adults presenting with possible low mood, begin the consultation by asking two direct screening questions: “Over the past 2 weeks, have you felt down, depressed, or hopeless?” and “Over the past 2 weeks, have you felt little interest or pleasure in doing things?” – this approach is recommended by the American College of Physicians based on evidence from the Annals of Internal Medicine. 26

Clarifying Symptom Terminology

When patients use vague descriptors such as “memory loss,” “confusion,” or “low mood,” request concrete examples of what they mean, because lay definitions often differ from clinical definitions – improves diagnostic accuracy. 27

Temporal Profile of Mood Symptoms

Ask patients to specify when the mood symptoms first appeared, how their frequency and intensity have changed over time, and whether the course is episodic or persistent; this helps distinguish acute reactions from chronic depressive disorders. 27

Contextualizing Triggering Events

Explore any events that patients associate with the onset of their mood symptoms (e.g., surgery, trauma) while separating the patient’s perceived cause from the clinical symptom description to avoid premature attribution. 27

Avoiding Normal‑Aging Assumptions

Do not accept “normal aging” or ordinary stress as sufficient explanations for depressive symptoms without a thorough evaluation; systematic assessment is required to rule out pathological depression. 27

Collateral Information from Informants

When feasible, interview a family member or other informant separately from the patient; discrepancies between patient and informant reports provide valuable diagnostic clues about mood and behavioral changes. 27

Recognizing Informant Insight Gaps

Be aware that patients and their companions may not recognize that behavioral or mood changes are related to the presenting problem; obtaining independent collateral information can uncover hidden symptoms. 27

PHQ‑2 Depression Screening: Diagnostic Performance and Clinical Implementation

Screening Tool Characteristics

The PHQ‑2 is an ultra‑brief, two‑item questionnaire that asks about depressed mood and loss of interest over the past two weeks, with each item scored 0–3 for a total possible score of 0–6【28】.

Diagnostic Accuracy

In primary‑care populations, a PHQ‑2 cutoff ≥ 3 yields a sensitivity of approximately 74 % and a specificity of about 75 % for detecting major depressive disorder【28】.
Using a lower cutoff ≥ 2 increases sensitivity to 86–91 % but reduces specificity to 70–78 %, capturing more true cases at the expense of more false‑positive results【28】.

Two‑Stage Screening Algorithm

The recommended workflow is to administer the PHQ‑2 first; patients scoring ≥ 3 should immediately receive the full PHQ‑9 to assess severity and guide management【28】【29】.
This gated approach requires only 1–2 minutes for the PHQ‑2 compared with 3–5 minutes for the PHQ‑9, reducing the screening burden in busy primary‑care settings【28】.
The two‑stage method maintains reasonable detection rates while reserving the longer PHQ‑9 for individuals who screen positive on the PHQ‑2【29】.

Limitations and Suicide Risk Assessment

The PHQ‑2 omits the suicide item (item 9 of the PHQ‑9), so relying on it alone can miss patients with suicidal ideation who may not endorse the two core depressive symptoms【30】【29】.
Consequently, clinicians should never use the PHQ‑2 as the sole depression assessment tool and must follow any positive PHQ‑2 screen with the full PHQ‑9 to capture suicide risk【29】.
In high‑risk populations or when suicide screening is a priority, it is advisable to start directly with the PHQ‑9【28】.

Implementation Protocols

Effective PHQ‑2 screening programs require clear protocols for managing positive results; screening without defined intervention pathways does not improve patient outcomes【30】【29】.
Key implementation elements include designated staff responsibilities for administering and scoring the PHQ‑2, established referral pathways to mental‑health specialists for moderate‑to‑severe cases, and availability of treatment resources for patients who screen positive【28】.